# Sermorelin vs CJC-1295: Native GHRH(1-29) Against a Long-Acting Analog

> Sermorelin vs CJC-1295: native GHRH(1-29) clears in ~10-12 minutes; CJC-1295's DAC chemistry extends GHRH-axis action for days. A cited comparison of two GHRH-axis secretagogues by half-life and design.

Two panels, one axis: the short-lived native fragment, and the half-life-extension chemistry built to outlast it.

## The short version

Sermorelin vs CJC-1295 is, at heart, a half-life story. Both are GHRH-axis secretagogues — both tell the pituitary to release the body's own growth hormone. Sermorelin is the plain native fragment: it clears from the blood in about 10-12 minutes [3]. CJC-1295 is an engineered relative built to last far longer, using chemistry that grabs onto a blood protein so it isn't cleared as fast [10]. So the comparison is not "which is stronger" but "native and brief" versus "modified and long-acting." This page lays both side by side and cites the pharmacokinetics to source.

## Native GHRH(1-29): short by design

Sermorelin is the unmodified active fragment of GHRH. Its pharmacokinetics are well characterized: in 30 healthy men, intravenous GHRH(1-29)NH2 elicited significant GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg [3]. The plasma half-life is on the order of 10-12 minutes — the peptide is rapidly eliminated — yet a single dose keeps serum GH elevated for roughly 3 hours [3]. Intranasal bioavailability in the same work was only 3-5% [3], which is why subcutaneous injection is the route studied and why oral and sublingual formulations draw consistent criticism in research-user communities.

That brevity is the whole point of comparison. The native peptide does its job and clears — a clean, feedback-respecting pulse, but a short one.

## Why CJC-1295 exists: half-life extension

CJC-1295 is what happens when chemists set out to keep a GHRH signal in circulation. The native peptide's short half-life [3] motivated longer-acting analogs through two strategies catalogued in the GRF-analogue literature: stabilizing substitutions such as D-Ala2 to resist enzymatic breakdown, and conjugation chemistry to slow clearance [10]. A review of PEGylation of GHRH (GRF) analogues describes attaching polyethylene-glycol chains to prolong action; the DAC (Drug Affinity Complex) approach behind CJC-1295 instead uses a maleimide group that binds serum albumin, tethering the peptide to a long-lived carrier protein [10].

The trade is design, not magnitude. Sermorelin reproduces the brief native pulse; CJC-1295's chemistry extends GHRH-axis exposure across a longer window. Both remain GHRH-receptor agonists acting on the same somatotroph pathway [11].

## Reading the two side by side

Set against [sermorelin's short half-life](/vs-cjc-1295), the contrast is clean. Native GHRH(1-29) clears in ~10-12 minutes and elevates GH for ~3 hours per dose [3] — a short, repeatable pulse that leans on bedtime timing to align with the body's largest natural nocturnal GH burst. The DAC-extended analog is engineered for a far longer duration of action from the same receptor mechanism [10][11].

For the receptor-level mechanism both share, see [the published human research](/research). For the doses used to study each in the literature, see [doses used in research](/dosage). The comparison ends where the evidence does: the native peptide's PK is precisely measured [3]; long-term human efficacy and safety data for adult use of either remain limited.

---

Script Sermorelin lays the GHRH(1-29) record out as a bento board of cited panels — the receptor mechanism, the pediatric and aging GH/IGF-1 figures, the cognition signal, and the honest gaps — a reference console for the literature, never a clinic, a pharmacy, or a prescription.